Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study

OBJECTIVES: Glucocorticoids have anti-inflammatory, transrepression-mediated effects, although adverse events (AEs; transactivation-mediated effects) limit long-term use in patients with rheumatoid arthritis (RA). We evaluated the efficacy and safety of fosdagrocorat (PF-04171327), a dissociated ago...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:RMD Open
Auteurs principaux: Buttgereit, Frank, Strand, Vibeke, Lee, Eun Bong, Simon-Campos, Abraham, McCabe, Dorothy, Genet, Astrid, Tammara, Brinda, Rojo, Ricardo, Hey-Hadavi, Judith
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2019
Sujets:
Rheumatoid Arthritis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6525626/
https://ncbi.nlm.nih.gov/pubmed/31168411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2018-000889
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires